Trials / Recruiting
RecruitingNCT07107607
Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)
Cannabis as an Anti-cancer Agent: A Review of Medical Records in Patients With Cancer to Assess Potential Anti-cancer Benefits From Using Cannabis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- HealthPartners Institute · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
Detailed description
The purpose of the study is to further assess how cannabis may help control cancer growth and attempt to validate such claims. To do this, the investigators will review medical records from consented patients who report that cannabis has helped to reduce or control growth of cancer by assessing prior cancer treatments and assessments (for example, cancer/tumor labs like prostate-specific antigen (PSA), cancer antigen (CA)-125, carcinoembryonic antigen (CEA) and radiology imaging reports such as computed tomography (CT) scan, positron emission tomography (PET)/CT scan, and magnetic resonance imaging (MRI)) as well as cannabis use details.
Conditions
Timeline
- Start date
- 2021-03-19
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2025-08-06
- Last updated
- 2025-08-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07107607. Inclusion in this directory is not an endorsement.